xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.
Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O.
Yoshikawa M, et al. Among authors: kawashiri s.
Cancer Res. 2013 Mar 15;73(6):1855-66. doi: 10.1158/0008-5472.CAN-12-3609-T. Epub 2013 Jan 14.
Cancer Res. 2013.
PMID: 23319806